OakChart

Exicure Inc

XCURHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:58 PM ET

1.11+0.03 (2.78%)
2026-11-12 04:08 CET
Market cap
7.27 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-8.28 USD m
Free cash flow, TTM
-6.38 USD m
EPS diluted, TTM
-1.30
P/E
-
Compare

Price

XCUR against its 20, 50 and 200-day averages
2050200
1.002.003.004.005.006.2M12.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26XCURclose 1.1120-day 1.0350-day 1.15200-day 2.521.1152w low

88.3% under the 52-week high of 9.48 on 9 Dec 2025. 52-week low 0.78 on 10 Nov 2026. Last 15 sessions, 64.7% high to low

Volume 1.46× normal · the line is the 50-bar volume average

Profile

XCUR
52-week range, 4% of the way up
0.789.48

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Employees8
IPOMay 22, 2018
Beta3.73
ATR, 14d0.13
Rel volume1.46
Short float1.40%
Insider own42.98%
Inst own2.28%

Snapshot

6 groups

Valuation

Index-
Market Cap7.27M
Enterprise Value5.55M
Income-8.28M
Sales0.00M
Book/sh0.15
Cash/sh0.26
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPOMay 22, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B7.24
P/C4.22
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.56
Current Ratio0.56
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.30
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y34.50% 54.97%
Sales past 3/5Y- -
EPS Y/Y TTM23.05%
Sales Y/Y TTM-100.00%
EPS Q/Q57.60%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own42.98%
Insider Trans0.00%
Inst Own2.28%
Inst Trans-2.16%
ROA-54.98%
ROE-168.37%
ROIC-847.90%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA208.17%
SMA50-3.14%
SMA200-55.99%
Trades-

Technical

Shs Outstand6.37M
Shs Float3.73M
Short Float1.40%
Short Ratio0.92
Short Interest0.05M
52W High9.48 -88.29%
52W Low0.78 42.86%
Volatility18.45% 13.75%
ATR (14)0.13
RSI (14)53.46
Beta3.73
Rel Volume1.46
Avg Volume56.70K
Volume82,522

Performance

Perf Week11.81%
Perf Month-3.48%
Perf Quarter-15.27%
Perf Half Y-64.65%
Perf YTD-79.52%
Perf Year-70.24%
Perf 3Y-62.63%
Perf 5Y-99.34%
Perf 10Y-
Recom1.00
Target Price10.33
Prev Close1.08
Price1.11
Change %2.78%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Dec 13, 2021DowngradeCChardan Capital MarketsBuy → Neutral$2.25 → $0.40-64.0%
Dec 18, 2020InitiatedBBMO Capital MarketsOutperform$6+440.5%
Nov 20, 2019InitiatedGGuggenheimBuy$9+710.8%

Peers

Mkt cap
TickerCompanyMkt cap
BLRXBioline Rx Ltd ADR7.42M
JSPRJasper Therapeutics Inc16.37M
MBRXMoleculin Biotech Inc8.50M
VORVor Biopharma Inc1.23B
CTXRCitius Pharmaceuticals Inc13.20M
TCRTAlaunos Therapeutics Inc6.65M
ESLAEstrella Immunopharma Inc34.53M
ONCOOnconetix Inc2.21M
INDPIndaptus Therapeutics Inc493.00M
SCNIScinai Immunotherapeutics Ltd ADR0.69M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Exicure HiTron Inc.10% OwnerJan 21 '26Sale4.50258,3671,162,6521,598,947Jan 21 12:46 PM
Exicure HiTron Inc.10% OwnerJan 16 '26Sale4.50734,7473,306,3621,857,314Jan 20 02:09 PM
Exicure HiTron Inc.10% OwnerJan 07 '26Sale4.50741,2723,335,7242,592,061Jan 08 08:42 PM
SANGSANGIN INVESTMENT & SECURI10% OwnerDec 08 '25Sale8.71433,3323,774,3220Dec 10 08:51 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion (GlobeNewswire) +21.31%
  • Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement (GlobeNewswire)
  • Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance (GlobeNewswire)
  • Exicure Announces Board and Committee Changes (GlobeNewswire) -5.45%
  • Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement (GlobeNewswire)
  • Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q (GlobeNewswire) -6.61%
  • Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) (GlobeNewswire)
  • Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions (GlobeNewswire)
  • Exicure, Inc. Reports Full Year 2025 Financial Results (GlobeNewswire)
  • Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant (GlobeNewswire)
  • Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings (GlobeNewswire)
  • Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting (GlobeNewswire) +8.78% +36.77%
  • Exicure, Inc. Reports Third Quarter 2025 Financial Results (GlobeNewswire) -6.82%
  • New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025Q32025-11-07---0.390---
2025Q22025-08-08---0.410---
2024Q32024-11-14---0.570---
2024Q12024-06-17---0.1000.50--
2023Q32024-05-16---0.610---
2023Q22023-08-11---0.680---
2023Q12023-07-14---0.700---
2022Q42023-03-2721.200-18.52221.77--
2022Q32022-11-14-5.200--5.1982.02-1
2022Q22022-08-15-8.300-6.000-8.2932.474.101
2022Q12022-05-16-10.500-10.500-10.3552.574.301
2021Q42022-03-25-22.500-21.000-23.4022.123.501
2021Q32021-11-19-40.500-13.875-40.062-3.686.994
2021Q22021-08-12-24.000-21.000-24.3110.081.555
2021Q12021-05-12-21.000-18.600-21.3031.001.64-
2020Q42021-03-11-21.000-15.600-21.8100.142.47-

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-81.000-88.500-81.6230.120.11
2019FY-69.000-61.500-68.4121.301.07
2020FY-42.000-35.700-42.43216.6118.96
2021FY-0.720--108.5-0.48-
2022FY-2.800--2.80028.83-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-163.214-81.623-68.412-42.432-108.504-2.795-10.553-4.748-0.785-1.3028
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.347-0.574-1.1920.487-0.415-0.386-0.455-0.287-0.176
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual9.7190.1181.29616.613-0.48328.82600.500
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.2620.2960.5740.5840.7250.9931.736.0276.3746.374
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.732.1726.0276.3186.3186.3746.3746.3746.374
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.500.0028.83-0.4816.611.300.12
Cost of Goods Sold Incl. D&A0.370.460.821.381.861.78---
Gross Profit-0.37-0.46-0.32-1.3826.97-2.26---
Selling, General and Administrative Excl. Other6.949.664.6212.7028.8057.9040.6027.1921.58
Research and Development2.033.290.000.0517.9146.5830.6519.3414.12
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-7.31-10.12-4.95-14.08-1.83-60.16-25.44-26.62-21.82
Interest Expense0.000.000.020.000.591.690.570.790.67
Unusual Expense1.34-4.776.882.000.002.37-0.40-0.380.27
Net Income Before Taxes-8.92-5.58-9.69-16.91-2.37-64.10-24.67-26.30-22.41
Income Taxes-0.63-0.630.010.000.210.000.000.000.00
Consolidated Net Income-8.28-4.95-9.70-16.91-2.58-64.10-24.67-26.30-22.41
Net Income From Continuing Operations-8.28-4.95-9.70-16.91-2.58-64.10-24.67-26.30-22.41
Net Income-8.28-4.95-9.70-16.91-2.58-64.10-24.67-26.30-22.41
EPS (Recurring)-1.15-1.32-2.39-9.68-2.79-105.69-42.91-69.11-80.92
EPS (Basic, Before Extraordinaries)-1.30-0.79-4.75-10.55-2.79-108.50-42.43-68.41-81.62
EPS (Diluted)-1.30-0.79-4.75-10.55-2.79-108.50-42.43-68.41-81.62
EBITDA-6.94-9.66-4.12-12.700.03-58.38-23.99-25.89-21.46
Non-Operating Income (Expense)-0.27-0.232.15-0.840.050.120.940.720.35
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.000.021.351.082.942.181.841.81
Price To Earnings Ratio---0.34-----
Price To Sales Ratio--55.86-0.18-9.29127.271,235.68
Gross Margin---64.80-93.56468.32---
Operating Margin---989.80--6.3512,455.49-153.11-2,053.78-18,490.68
Net Margin---1,940.20--8.9613,271.64-148.49-2,029.55-18,994.07
Shares Outstanding6.376.376.031.730.990.730.580.570.30
Market Capitalization7.277.2735.625.025.7121.99155.14246.16157.03

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.040.110.160.070.130.110.210.21
Gross Profit-0.04-0.11-0.16-0.07-0.13-0.11-0.21-0.21
Selling, General and Administrative Excl. Other1.021.502.102.322.322.921.231.23
Research and Development0.170.310.660.890.940.810.000.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.06-1.60-2.26-2.39-2.45-3.02-1.44-1.43
Interest Expense0.000.000.000.000.000.000.000.01
Unusual Expense0.050.191.010.090.16-5.845.741.14
Net Income Before Taxes-1.12-1.83-3.53-2.44-2.623.01-7.18-1.08
Income Taxes0.000.00-0.630.000.000.000.000.01
Consolidated Net Income-1.12-1.83-2.90-2.44-2.623.01-7.18-1.09
Net Income From Continuing Operations-1.12-1.83-2.90-2.44-2.623.01-7.18-1.09
Net Income-1.12-1.83-2.90-2.44-2.623.01-7.18-1.09
EPS (Recurring)-0.17-0.27-0.34-0.38-0.40-0.17-0.53-0.15
EPS (Basic, Before Extraordinaries)-0.18-0.29-0.45-0.39-0.410.49-1.19-0.57
EPS (Diluted)-0.18-0.29-0.45-0.39-0.410.49-1.19-0.57
EBITDA-1.02-1.50-2.10-2.32-2.32-2.92-1.23-1.23
Non-Operating Income (Expense)-0.01-0.04-0.260.04-0.010.200.001.50
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.00-0.00-0.00-0.010.01
Price To Sales Ratio------164.7713.18
Shares Outstanding6.376.376.376.376.326.326.032.17
Market Capitalization7.2727.1234.5525.8444.4884.2835.626.00

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments3.7512.510.828.5839.1482.08110.7926.2725.76
Short Term Receivables0.060.520.010.000.000.010.270.010.03
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.820.641.191.474.534.231.721.381.84
Total Current Assets4.6213.672.0210.0543.6786.32112.7827.6627.64
Net Property, Plant & Equipment0.310.036.579.7911.8812.732.461.061.32
Total Investments and Advances0.000.001.201.209.201.200.000.000.00
Intangible Assets8.180.000.00------
Deferred Tax Assets0.81--------
Other Assets0.931.361.782.290.120.190.030.030.03
Total Assets14.8515.0611.5823.3364.87100.44115.2628.7628.99
Short Term Debt Incl. Current Port. of LT Debt0.180.720.630.547.330.225.260.000.00
Accounts Payable1.691.031.630.363.411.871.810.501.05
Other Current Liabilities2.021.320.250.7423.3211.6424.021.542.31
Total Current Liabilities3.893.072.511.6434.0713.7331.092.043.36
Long Term Debt0.005.216.046.777.4024.550.064.924.86
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities1.23--------
Other Liabilities5.800.000.000.0012.160.663.370.840.80
Total Liabilities10.928.288.558.4153.6438.9434.527.809.01
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity3.936.773.0314.9211.2361.5180.7520.9519.98
Total Shareholders Equity3.936.773.0314.9211.2361.5180.7520.9519.98
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity3.936.773.0314.9211.2361.5180.7520.9519.98
Total Liabilities & Stockholders Equity14.8515.0611.5823.3364.87100.44115.2628.7628.99
Book Value Per Share0.621.121.7515.0215.49105.26140.7270.8576.24
Tangible Book Value Per Share-0.671.121.7515.0215.49105.26140.7270.8576.24
Full-Time Employees876134763292723
Price to Book Ratio7.2419.221.12-1.541.962.523.057.496.34
Return on Assets-33.08-72.84-96.91-5.86-77.55-22.87-36.53-78.90-44.43
Return on Equity-92.47-197.92-188.43-19.74-176.25-34.68-51.73-112.35-98.21
Return on Invested Capital-125.98-80.94-186.48-11.90-343.97-28.67-32.55-86.61-44.35
Quick Ratio1.194.450.816.131.286.293.6313.548.24
Current Ratio1.194.450.816.131.286.293.6313.548.24

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-8.28-4.95-9.70-16.91-2.58-64.10-24.67-26.30-22.41
Depreciation0.370.460.821.381.861.781.450.720.36
Other Funds (Non Cash)1.47-4.585.344.271.383.402.281.692.58
Funds from Operations-7.07-9.70-3.54-11.270.65-58.92-20.94-23.89-19.48
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.371.140.630.91-36.8124.11-18.3325.21-0.01
Cash from Operating Activities-6.70-8.55-2.91-10.36-36.16-34.82-39.271.32-19.49
Capital Expenditures0.32-0.000.000.00-0.01-0.97-3.17-1.08-0.09
Net Assets From Acquisitions-0.23-2.320.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.480.520.000.920.200.000.000.00-
Purchase or Sale of Investments0.000.000.00-2.004.5044.0513.31-62.350.00
Purchase of Investments0.000.000.00-2.00-1.50-6.50-56.64-62.350.00
Sale Or Maturity of Investments0.000.000.000.006.0050.5569.950.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.56-1.810.00-1.084.7043.0910.14-63.43-0.09
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.001.6012.403.804.9111.133.1384.5920.11
Repurchase of Common Pref Stock0.000.000.00-0.800.000.000.000.000.00
Sale of Common Pref Stock0.001.6012.404.604.9111.133.1384.5920.11
Proceedsfrom Stock Options0.001.6012.404.60-0.14-1.11-0.21-6.2420.07
Issuance or Reduction of Debt, Net0.000.001.000.00-7.50-10.0012.00-0.280.00
Change in Long Term Debt0.000.000.000.00-7.50-10.0012.00-0.280.00
Issuance of Long Term Debt0.000.000.000.000.000.0017.000.000.00
Reduction of Long Term Debt0.000.000.000.00-7.50-10.00-5.00-0.280.00
Net Financing Active Other Cash Flow0.000.000.00-0.12-0.00-0.010.000.000.00
Other Financing Activities Uses0.000.000.00-0.12-0.00-0.010.000.000.00
Cash from Financing Activities0.001.6013.403.67-2.601.1215.1384.3120.09
Net Change in Cash-6.14-8.7610.49-7.76-34.079.38-14.0022.190.50
Free Cash Flow-6.38-8.56-2.91-10.36-36.17-35.79-42.440.23-19.58
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-------701.88-
Deferred Taxes & Investment Tax Credit--0.630.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments1.722.603.754.447.8610.42
Short Term Receivables0.010.060.060.060.080.17
Inventories0.000.000.000.000.000.00
Other Current Assets0.600.870.820.950.710.71
Total Current Assets2.323.534.625.448.6511.30
Net Property, Plant & Equipment0.180.220.310.820.980.80
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets8.188.188.187.127.127.12
Deferred Tax Assets--0.81---
Other Assets0.710.820.931.891.991.45
Total Assets11.4012.7614.8515.2718.7420.68
Short Term Debt Incl. Current Port. of LT Debt0.000.020.180.340.480.59
Accounts Payable2.192.441.691.311.841.21
Other Current Liabilities1.991.992.021.122.252.09
Total Current Liabilities4.174.463.892.774.573.89
Long Term Debt0.000.000.000.030.000.03
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.420.421.23---
Other Liabilities5.835.775.805.545.315.38
Total Liabilities10.4210.6610.928.349.889.30
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity0.982.103.936.938.8611.38
Total Shareholders Equity0.982.103.936.938.8611.38
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity0.982.103.936.938.8611.38
Total Liabilities & Stockholders Equity11.4012.7614.8515.2718.7420.68
Book Value Per Share0.150.330.621.091.401.80
Tangible Book Value Per Share-1.13-0.95-0.67-0.030.280.67
Full-Time Employees228--8
Price to Book Ratio7.246.914.992.923.9111.87
Return on Assets-54.98-58.53-33.08-71.27-53.58-37.35
Return on Equity-168.37-145.16-92.47-217.87-150.50-86.28
Return on Invested Capital-114.74-87.13-73.82-35.05-29.5726.38
Quick Ratio0.560.791.191.961.892.91
Current Ratio0.560.791.191.961.892.91

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.12-1.83-2.90-2.44-2.623.01
Depreciation0.040.110.160.070.130.11
Other Funds (Non Cash)0.040.231.110.100.22-6.00
Funds from Operations-1.04-1.50-2.26-2.27-2.27-2.88
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.150.351.12-1.25-0.011.29
Cash from Operating Activities-0.89-1.14-1.15-3.53-2.28-1.60
Capital Expenditures0.000.000.210.11-0.320.00
Net Assets From Acquisitions0.000.00-0.230.000.00-2.09
Sale of Fixed Assets and Businesses0.000.000.470.000.040.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.460.11-0.28-2.09
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.000.001.60
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.001.60
Proceedsfrom Stock Options0.000.000.000.000.001.60
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.000.000.000.001.60
Net Change in Cash-0.89-1.14-0.69-3.42-2.56-2.09
Free Cash Flow-0.89-1.14-0.93-3.42-2.60-1.60

Revenue breakdown

Pharmaceutical Preparations2024: 500.00K
United States2024: 500.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.40%0.1M3.7M45.27K
2026-10-151.15%0.0M3.7M58.26K
2026-09-301.01%0.0M3.7M396.34K
2026-09-151.89%0.1M3.7M410.64K
2026-08-311.36%0.1M3.7M400.74K
2026-08-141.62%0.1M3.7M401.48K
2026-07-313.00%0.1M3.6M396.37K
2026-07-1514.15%0.5M3.6M378.98K
2026-06-300.16%0.0M4.2M25.04K
2026-06-150.35%0.0M4.2M18.93K
2026-05-290.49%0.0M4.2M18.07K
2026-05-150.77%0.0M4.2M18.88K
2026-04-301.24%0.1M4.2M22.15K
2026-04-151.38%0.1M4.2M26.78K
2026-03-311.37%0.1M4.2M32.68K
2026-03-131.40%0.1M4.2M44.44K
2026-02-271.71%0.1M4.2M692.22K
2026-02-131.49%0.1M4.2M694.62K
2026-01-302.21%0.1M4.0M691.18K
2026-01-152.21%0.1M4.0M676.14K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-04SEC
2026-11-02PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-02SEC
2026-09-168-KCurrent report2026-09-16SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-07-17SCHEDULE 13D/ASEC
2026-06-308-KCurrent report2026-06-30SEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-15NT 10-Q2026-03-31SEC
2026-04-108-KCurrent report2026-04-08SEC
2026-04-028-KCurrent report2026-04-02SEC
2026-03-278-KCurrent report2026-03-25SEC
2026-03-2510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-258-KCurrent report2026-03-25SEC
2026-02-194Statement of changes in beneficial ownership of securities2026-02-16SEC
2026-02-178-KCurrent report2026-02-11SEC
2026-02-108-KCurrent report2026-02-06SEC
2026-01-228-KCurrent report2026-01-16SEC
2026-01-21SCHEDULE 13D/ASEC
2026-01-214Statement of changes in beneficial ownership of securities2026-01-21SEC
2026-01-20SCHEDULE 13D/ASEC
2026-01-204Statement of changes in beneficial ownership of securities2026-01-16SEC
2026-01-09SCHEDULE 13D/ASEC
2026-01-084Statement of changes in beneficial ownership of securities2026-01-07SEC
2025-12-10SCHEDULE 13G/ASEC
2025-12-104Statement of changes in beneficial ownership of securities2025-12-08SEC
2025-11-194Statement of changes in beneficial ownership of securities2025-11-16SEC
2025-11-178-KCurrent report2025-11-10SEC
2025-11-108-KCurrent report2025-11-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-01007.80M3
2025-12003.77M1
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC0.68%
GEODE CAPITAL MANAGEMENT, LLC0.62%
JANE STREET GROUP, LLC0.46%
CITADEL ADVISORS LLC0.23%
VANGUARD FIDUCIARY TRUST CO0.21%
Tower Research Capital LLC0.06%
UBS Group AG0.05%
SBI Securities Co., Ltd.0.00%
MORGAN STANLEY0.00%
ROYAL BANK OF CANADA0.00%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.45%
Fidelity Extended Market Index Fund0.38%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.22%
Fidelity Nasdaq Composite Index Fund0.08%
Fidelity Total Market Index Fund0.07%
Fidelity Series Total Market Index Fund0.06%
Diversified Equity Alpha Master Portfolio0.00%

OakChart. XCUR. Cached 15 minutes.